|Particulars (In Rs. Cr.)||Q2FY21||Q1FY21||Q2FY20||QoQ %||YoY%|
|Revenue from Sales of Products||11510||10570||9931||8.89||15.90|
|Revenue from Sale of Services||10||2||26||400.00||-61.54|
|Other Operating Income||163||159||148||2.52||10.14|
|Revenue from Operations||11683||10731||10105||8.87||15.62|
|Raw Material Expenses||4279||3685||3331||16.12||28.46|
|Raw Material Expenses as % of Sales of Products||37.18%||34.86%||33.54%||–||–|
|EBITDA Margin||25.04%||25.11%||24.82%||(7) bps||22 bps|
|Profit After Tax||1974||1897||1818||4.06||8.58|
|PATM (%)||16.76%||17.43%||17.78%||(67) bps||(102) bps|
|Segment Revenue ( HUL+ GSK Consumer)||Q2FY21||Q1FY21||Q2FY20||QoQ %||YoY%|
|Beauty & Personal Care||4550||4043||4580||12.54||-0.66|
|Foods & Refreshment||3379||2958||1847||14.23||82.95|
HUL Consolidated revenue rose 15.6% over a year earlier to Rs 11,683 crore compared with the estimated Rs 11,154 crore.
Net profit of the company rose 8% year-on-year to Rs 1,974 crore in the three months ended September compared with the estimated Rs 2039.9 crore.
Revenue from sales of products came in at Rs 11,510 crore, up 15.19 per cent from Rs 10,223 crore a year ago.
Volumes rose 1% in the reported period, excluding the consumer businesses acquired from GlaxoSmithKline Plc and VWash.
The company declared an interim dividend of Rs 14 per share for 2020-21.
HUL’s health, hygiene and nutrition segment, which is 80% of its portfolio, grew 10% in the September quarter, on a YoY basis.
Contraction in its discretionary category comprising cosmetics, deodorants and ice-cream, which is 20% of the portfolio, narrowed. In the September quarter the decline was 25% y-o-y compared to a 45% decline in the June quarter.
In Beauty & Personal Care Segment Oral Care and Hair Care showed double digit growth. Oral Care Double-digit growth led by Close Up
Skin cleansing grew in double digits on the back of a very strong performance in ‘Lifebuoy’. Hand sanitizers and hand wash segments continued to gain penetration and have delivered robust growths
HUL Food and Refreshment Segment grew 19% excluding merger impact of GSK Consumer.
In Foods & Refreshment Tea and coffee continue to outperform. Double digit growth across Tea brands; unprecedented tea inflation managed well
Both Kissan and Knorr seeing strong consumer traction
The company is witnessing raw material inflation in some of the categories.
Household care grew double digit driven by Domex, the range has expanded pan India in Q2
The company cut prices in its fabric wash category by 2.5% to pass the benefits of lower input costs.
Commenting In the context of a challenging economic environment, our growth has been competitive and profitable,” Sanjiv Mehta, chairman and managing director at HUL, said in a post-earnings call. “Rural markets have been resilient but demand in urban markets, especially metros has been muted.”
All-round Cautious Optimism: The worst is possibly behind us; business picking up momentum
Rural growths looking resilient and need to sustain. Urban demand outlook uncertain
Inflation in select categories to continue; gross margins likely to remain under pressure
The management expects demand for items such as skin care and deodorants to improve as people start moving out of their homes. However, rural demand is expected to grow faster than urban demand
HUL has increased direct coverage by 10% from the pre-covid levels, while ecommerce contribution and growth up 2x at 6%.
HUL Revenue for the Q2FY21 beats the street estimates, however profit impacted due to higher raw material cost and tax. Though higher input prices would put margins under pressure in the near term, the management has maintained outlook of sustenance of modest margin expansion in the coming years. Oral Care is seeing healthy growth since past few quarters owing to recovery in Close-up brand Managements has a strategy in mind to revive growth of Pepsodent, which is flagging brand. We remain positive on Hindustan Unilever from a long-term perspective, encouraged by robust earnings growth potential beyond the near term owing to its portfolio and execution strengths, and significant synergies in FY22E as a result of acquisition Horlicks and boost from GlaxoSmithKline. The company’s earnings growth has gained further momentum in recent years growing at 18% EPS CAGR in the past 5 years. Valuing the company at 58x FY21E merged EPS, we recommend buy on HUL for the Target Price of Rs. 2,600.
DISCLOSURE IN PURSUANCE OF SECTION 19 OF SEBI (RA) REGULATION 2014
Elite Wealth Advisors Limited does/does not do business with companies covered in its research reports. Investors should be aware that the Elite Wealth Advisors Limited may/may not have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as read more
For Daily Share Market Updates, Daily debt market review, Market Research Analysis reports, Weekly Techno-Funda Report, Fundamental Analysis Report, Monthly Recommended stock Picks, Equity Trading Tips, Upcoming IPO/NFO/Bonds/Ncd’s updates & other related information Subscribe our research plan